<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Clinical manifestations and diagnosis of HIV-2 infection</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Clinical manifestations and diagnosis of HIV-2 infection</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Clinical manifestations and diagnosis of HIV-2 infection</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Geoffrey S Gottlieb, MD, PhD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">John A Bartlett, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jennifer Mitty, MD, MPH</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Feb 02, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H15783692"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Although HIV-1 infection is associated with most of the global AIDS pandemic, HIV-2 is an important cause of disease in West Africa, where it is endemic. HIV-2 infection has also been described in locales with cultural and socioeconomic ties to West Africa, including the United States. It is an important consideration in patients with an AIDS-like illness or among persons with epidemiologic risk factors for infection [<a href="#rid1">1</a>]. Epidemiologic risk factors are similar to HIV-1 infection and include a past history of blood transfusion or having a sex partner or needle-sharing partner with HIV-2 infection or perinatal transmission from an HIV-2-infected mother. </p><p>This topic will address the clinical manifestations and diagnosis of HIV-2 infection. The epidemiology, transmission, natural history, pathogenesis and treatment of HIV-2 are discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/13966.html" rel="external">"Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection"</a> and  <a class="medical medical_review" href="/z/d/html/16252.html" rel="external">"Treatment of HIV-2 infection"</a>.)</p><p class="headingAnchor" id="H605658"><span class="h1">STAGING OF DISEASE</span><span class="headingEndMark"> — </span>In persons living with HIV-1, two important laboratory determinants of the rate of progression are the CD4 cell count and the plasma viral load [<a href="#rid2">2,3</a>]. In untreated patients, the average rate of decline of CD4 cells ("CD4 slope") is about 50/mm<sup>3</sup> per year and the average plasma RNA viral load (without therapy) is 30,000 to 50,000 copies/mL [<a href="#rid2">2-4</a>]. Patients with a CD4 cell count &lt;200 cells/mm<sup>3</sup> are considered to have AIDS; such patients are at significantly increased risk for opportunistic infections and AIDS-related malignancies. (See  <a class="medical medical_review" href="/z/d/html/3724.html" rel="external">"The natural history and clinical features of HIV infection in adults and adolescents"</a>.)</p><p>There are far fewer data on the CD4 threshold that is associated with an increased risk of AIDS and opportunistic infections among HIV-2 infected patients. Most experts apply the same CD4 cell count threshold (&lt;200 cells/mm<sup>3</sup>) as a laboratory parameter indicating AIDS in persons living with HIV-2. </p><p>Laboratory monitoring for HIV-2 RNA viral load is problematic since testing availability is more limited. Most commercial laboratories do not offer testing for HIV-2 RNA viral load and the few that do offer only qualitative testing (eg, Quest Diagnostics laboratories). Quantitative HIV-2 RNA viral load testing may be obtained from the following laboratories [<a href="#rid5">5-8</a>]: </p><p class="bulletIndent1"><span class="glyph">●</span>University of Washington Lab Medicine Community Services: (phone 1-800-713-5198 or <a class="__cf_email__" data-cfemail="ff9c9092928c9a8d89bf8a88d19a9b8a" href="/cdn-cgi/l/email-protection">[email protected]</a>) <a class="external" href="/external-redirect?target_url=https%3A%2F%2Fdlmp.uw.edu%2Fsite%2Fcontact&amp;token=zpNCX14A2R12bA0oIWem49nKG4OC3fUFqGl9yj7iUjaCbBrNdkjod6HUzp5MDIeJ&amp;TOPIC_ID=16727" target="_blank">https://dlmp.uw.edu/site/contact</a></p><p></p><p class="bulletIndent1"><span class="glyph">●</span>New York State Department of Health Lab: (phone 518-473-6007) <a class="external" href="/external-redirect?target_url=http%3A%2F%2Fwww.wadsworth.org%2Fprograms%2Fid%2Fbloodborne-viruses%2Fclinical-testing%2Fhiv-2-nucleic-acid&amp;token=maHMlRbuVtQiq5YNS9JBc371l1wgDb%2FKyPPP8di7y0zHIP35XPBxLbDheW1p862UzpXwUcjslnL66%2FhCiXOo7%2FRGKRdRuR%2BCWFh8X4jJ3a%2FILOHzfjCA3qHJurdogkys&amp;TOPIC_ID=16727" target="_blank">http://www.wadsworth.org/programs/id/bloodborne-viruses/clinical-testing/hiv-2-nucleic-acid</a></p><p></p><p>Laboratories that perform HIV-2 RNA quantitative testing report generally lower levels of HIV-2 viremia compared with patients with HIV-1 [<a href="#rid5">5-13</a>]. </p><p class="headingAnchor" id="H605843"><span class="h1">RISK FACTORS FOR CLINICAL PROGRESSION</span><span class="headingEndMark"> — </span>Several factors contribute to HIV-1 disease progression including viral fitness, genetic factors, HIV coreceptor usage, nutritional status, as well as other comorbidities. However, the cofactors that lead to progression of HIV-2 infection are not as well understood. </p><p class="headingAnchor" id="H15783699"><span class="h1">CLINICAL MANIFESTATIONS</span></p><p class="headingAnchor" id="H605740"><span class="h2">Primary HIV-2 infection</span><span class="headingEndMark"> — </span>There are scant data on the clinical presentation of acute HIV-2 infection [<a href="#rid14">14,15</a>]. </p><p class="headingAnchor" id="H605774"><span class="h2">Chronic infection</span><span class="headingEndMark"> — </span>Compared with HIV-1, HIV-2 infection is characterized by a longer asymptomatic stage of infection and slower declines of CD4+ T-cell counts [<a href="#rid9">9-13,16-25</a>]. (See  <a class="medical medical_review" href="/z/d/html/13966.html" rel="external">"Epidemiology, transmission, natural history, and pathogenesis of HIV-2 infection"</a>.) </p><p>However, the clinical manifestations of advanced HIV-2 infection are generally similar to those reported for HIV-1 [<a href="#rid26">26</a>]. Once advanced immunosuppression has occurred (eg, CD4 cell count &lt;200 cells/mm<sup>3</sup>), persons living with HIV-2 are at risk for similar types of opportunistic infections, such as tuberculosis, pneumocystis, toxoplasmosis, and cryptococcal disease. Although some studies have suggested that there may be some subtle differences in the frequencies of reported opportunistic infections in persons living with HIV-2, these observational data are limited by small numbers of patients [<a href="#rid27">27-33</a>]. </p><p>The history and physical examination for persons living with HIV-2 should be detailed and extensive, similar to that of the HIV-1, as discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3745.html" rel="external">"Primary care of adults with HIV"</a>.)</p><p class="headingAnchor" id="H15783706"><span class="h1">TESTING FOR HIV-2 INFECTION</span><span class="headingEndMark"> — </span>As in HIV-1 infection, patients should have serologic testing for HIV-2 infection with confirmatory testing. (See  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection", section on 'Testing algorithm'</a>.)</p><p>Screening antibody tests approved by the US Food and Drug Administration to detect and differentiate HIV-2 infection from HIV-1 include the BioPlex 2200 HIV Ag-Ab assay (Bio-Rad Laboratories) and the Geenius HIV 1/2 Supplemental Assay [<a href="#rid34">34</a>]. </p><p>A reactive result may be confirmed with a supplemental HIV-2 antibody test or an HIV-2 specific nucleic acid test. These tests include: </p><p class="bulletIndent1"><span class="glyph">●</span>An HIV-2 specific immunoblot assay (eg, Western blot)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An HIV-2 specific enzyme immunoassay </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Real-time polymerase chain reaction (RT-PCR) testing for the viral isolate itself (DNA/RNA)</p><p></p><p>Supplemental HIV-2 testing is available through the United States Centers for Disease Control and Prevention, or may be obtained through commercial testing laboratories, such as Pathology Associates Medical Laboratories (PAML) or Quest Diagnostics in the United States [<a href="#rid35">35,36</a>]. Qualitative HIV-2 DNA/RNA testing through RT-PCR testing can be obtained through Quest Diagnostics [<a href="#rid36">36</a>] and the University of Washington Clinical Labs [<a href="#rid37">37</a>]. Quantitative HIV-2 RNA testing may be obtained as described above. (See <a class="local">'Staging of disease'</a> above.)</p><p>Outside of the United States, supplemental HIV-2 antibody assays that are commercially available include: SD Bioline (Standard Diagnostics), INNO-LIA HIV I/II Score (Innogenetics NV), and HIV-2 Blot (MP Biomedials, LLC). Point-of-care HIV-2 nucleic acid (DNA/RNA) qualitative detection and differentiation (from HIV-1) can be performed using the Alere Detect Assay [<a href="#rid38">38-40</a>].</p><p class="headingAnchor" id="H15783734"><span class="h1">DIAGNOSTIC ISSUES RELATED TO HIV-1 WESTERN BLOT TESTING</span></p><p class="headingAnchor" id="H605877"><span class="h2">General background</span><span class="headingEndMark"> — </span>Clinicians need to be aware that all commercially available HIV-1 Western Blot assays may fully or partially cross-react with HIV-2, giving positive, indeterminate, or negative results that could lead to an incorrect diagnosis of HIV-1 infection or a missed diagnosis of HIV-2 [<a href="#rid41">41</a>]. </p><p>These diagnostic issues were well illustrated by results of an HIV-2 surveillance survey performed by the CDC in 2009, where the vast majority of cases were suspected because of inconsistent clinical or laboratory data [<a href="#rid42">42</a>]. Of 166 cases with HIV-2 infection, 56 percent of patients had an indeterminate HIV-1 immunoblot despite a positive HIV-1 or HIV-1/HIV-2 antibody screening test; 41 percent had an undetectable HIV viral load despite a positive HIV-1 immunoblot; and less than 1 percent had a negative HIV-1 immunoblot despite a positive HIV-1 or HIV-1/HIV-2 antibody screening test. </p><p>The Centers for Disease Control and Prevention has issued recommendations for a new HIV testing algorithm that includes initial screening with a fourth generation Ag/Ab HIV-1/2 immunoassay and confirmatory testing with a HIV-1/HIV-2 antibody differentiation immunoassay [<a href="#rid43">43</a>]. In addition to improving early HIV-1 detection and diagnosis, this new algorithm will likely increase HIV-2 diagnoses, and eliminate misclassification of HIV-2 resulting from a cross-reactive western blot. A detailed discussion on HIV testing is found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3736.html" rel="external">"Screening and diagnostic testing for HIV infection", section on 'Testing algorithm'</a>.)</p><p class="headingAnchor" id="H605884"><span class="h2">Interpretation of Western blot test results</span><span class="headingEndMark"> — </span>Previously recommended antibody testing included a screening enzyme immunoassay (EIA, which can also be referred to as a third generation antibody test) followed by a confirmatory Western blot if the EIA is positive. If such testing was performed in a patient with suspected HIV-2 infection, the interpretation and evaluation of various possible HIV immunoblot results are as follows:</p><p class="headingAnchor" id="H15783741"><span class="h3">A reactive HIV-1 Western blot</span><span class="headingEndMark"> — </span>A confirmatory Western blot for HIV-1 can be reactive due to true infection with HIV-1 or cross-reactivity to HIV-2 proteins [<a href="#rid44">44</a>]. Thus, this laboratory profile can represent three possible scenarios: monoinfection with HIV-1, monoinfection with HIV-2, or dual infection with both viruses. </p><p>If HIV-2 infection is suspected (eg, the patient is from West Africa), further testing with a specific HIV-2 Western blot is recommended. If the HIV-2 Western blot is negative, the patient can be assumed to have HIV-1 monoinfection. If the HIV-2 Western blot is reactive, the patient may have monoinfection with HIV-2 or dual infection with both HIV-1 and HIV-2. Further testing for HIV-1 RNA/DNA and HIV-2 RNA/DNA should be performed.</p><p class="headingAnchor" id="H15783748"><span class="h3">An indeterminate HIV-1 Western blot</span><span class="headingEndMark"> — </span>An indeterminate Western blot can infer acute HIV-1 infection or chronic HIV-2 infection. Further testing for HIV-1 RNA is indicated for the possibility of acute HIV-1 infection; if HIV-1 RNA is not detected, then HIV-2 Western blot testing and HIV-2 RNA/DNA should be performed [<a href="#rid41">41</a>]. </p><p class="headingAnchor" id="H15783755"><span class="h3">A negative HIV-1 Western blot</span><span class="headingEndMark"> — </span>A patient with a reactive HIV serology, but a negative confirmatory HIV-1 Western blot, may have HIV-2 infection. Thus, further testing with a specific HIV-2 Western blot test and HIV-2 RNA/DNA should be performed, particularly in persons with epidemiologic risk factors [<a href="#rid41">41</a>]. </p><p class="headingAnchor" id="H15783769"><span class="h1">WHEN TO SUSPECT HIV-2 INFECTION</span><span class="headingEndMark"> — </span>Clinicians must have a high index of suspicion for the diagnosis of HIV-2 infection since laboratory testing results can lead to diagnostic confusion, as discussed above [<a href="#rid41">41</a>]. Patients with a diagnosis of HIV-1 infection may actually be infected with HIV-2 or may be dually infected with both viruses. Certain clinical or laboratory clues should lead to further patient evaluation and testing, as discussed below [<a href="#rid45">45</a>]. </p><p class="headingAnchor" id="H15783783"><span class="h2">Clinical clues to possible HIV-2 infection</span><span class="headingEndMark"> — </span>HIV-2 diagnostic testing should be considered when clinical or laboratory data are incongruent. As examples: </p><p class="bulletIndent1"><span class="glyph">●</span>A patient from an HIV-2 endemic area, who presents with an opportunistic infection (eg, pneumocystis) or an AIDS-related clinical condition, and is found to be HIV-1 seronegative</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An HIV-1 seropositive patient with no detectable plasma HIV-1 RNA on ART who has a declining CD4 cell count</p><p></p><p class="headingAnchor" id="H15783790"><span class="h2">Laboratory clues for possible HIV-2 infection</span><span class="headingEndMark"> — </span>HIV-2 infection may also be suspected in the following scenarios: </p><p class="bulletIndent1"><span class="glyph">●</span>An untreated HIV-1 seropositive patient who has a low or undetectable viral load</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An HIV-1 seropositive patient with a virus that cannot be genotyped on routine HIV-1 drug resistance testing</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>An HIV seropositive patient with a Western blot test that is reported as "indeterminate". An indeterminate Western blot is characterized by an unusual pattern of HIV proteins (such as HIV "gag" plus "pol" without "env"). (See <a class="local">'An indeterminate HIV-1 Western blot'</a> above.)</p><p></p><p class="headingAnchor" id="H15783797"><span class="h1">WHO SHOULD BE SCREENED?</span><span class="headingEndMark"> — </span>The Centers for Disease Control (CDC) also recommends screening for HIV-2 infection in asymptomatic persons who are at risk for HIV-2 infection, including [<a href="#rid1">1,41</a>]:</p><p class="bulletIndent1"><span class="glyph">●</span>Persons from endemic areas</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sex partners and needle-sharing partners of persons with a diagnosis of HIV-2 infection</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Sex partners and needle-sharing partners of persons from endemic areas </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Children of women with a diagnosis of HIV-2 or risk factors for HIV-2 infection </p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Persons with a history of a blood transfusion in an endemic area</p><p></p><p>Locales where the prevalence of HIV-2 infection is considered "endemic" include all countries in West Africa: Benin, Burkina-Faso, Cape Verde, Cote d’Ivoire (Ivory Coast), Gambia, Ghana, Guinea, Guinea-Bissau, Liberia, Mali, Mauritania, Niger, Nigeria, Senegal, Sierra Leone, and Togo. </p><p class="headingAnchor" id="H643008091"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/111582.html" rel="external">"Society guideline links: Sexually transmitted infections"</a>.)</p><p class="headingAnchor" id="H15783818"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical manifestations</strong> – The clinical manifestations of advanced HIV-2 infection are generally similar to those reported for HIV-1. Once advanced immunosuppression has occurred (eg, CD4 cell count &lt;200 cells/mm<sup>3</sup>), patients with HIV-2 are at risk for similar types of opportunistic infections, such as pneumocystis and cryptococcal disease. (See <a class="local">'Clinical manifestations'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Types of tests</strong> – The HIV antibody tests approved by the US Food and Drug Administration to detect and differentiate HIV-2 infection from HIV-1 include the Geenius HIV 1/2 Supplemental Assay and the BioPlex 2200 HIV Ag-Ab assay. A reactive result may be confirmed with a supplemental HIV-2 antibody test or a DNA/RNA test. (See <a class="local">'Testing for HIV-2 infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>When to suspect HIV-2 infection</strong> – The possibility of HIV-2 infection should be considered in: a) persons from an endemic area who present with an AIDS-like illness, b) an untreated HIV-1 seropositive patient with a low or non-detectable viral load, or c) an HIV-1 seropositive patient with no detectable HIV-1 RNA with declining immunity despite antiretroviral therapy. (See <a class="local">'When to suspect HIV-2 infection'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Screening for HIV-2 infection</strong> – HIV-2 screening should be considered among asymptomatic persons who are at risk of infection. Such persons include those who have lived in endemic areas or who are sexual partners or needle-sharing partners of persons at risk for HIV-2 infection. (See <a class="local">'Who should be screened?'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Campbell-Yesufu OT, Gandhi RT. Update on human immunodeficiency virus (HIV)-2 infection. Clin Infect Dis 2011; 52:780.</a></li><li><a class="nounderline abstract_t">Mellors JW, Rinaldo CR Jr, Gupta P, et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272:1167.</a></li><li><a class="nounderline abstract_t">Mellors JW, Muñoz A, Giorgi JV, et al. Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection. Ann Intern Med 1997; 126:946.</a></li><li><a class="nounderline abstract_t">Vlahov D, Graham N, Hoover D, et al. Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count. JAMA 1998; 279:35.</a></li><li><a class="nounderline abstract_t">Damond F, Benard A, Ruelle J, et al. Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006. J Clin Microbiol 2008; 46:2088.</a></li><li><a class="nounderline abstract_t">Damond F, Benard A, Balotta C, et al. An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study. J Clin Microbiol 2011; 49:3491.</a></li><li><a class="nounderline abstract_t">Chang M, Gottlieb GS, Dragavon JA, et al. Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform. J Clin Virol 2012; 55:128.</a></li><li><a class="nounderline abstract_t">Styer LM, Miller TT, Parker MM. Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control. J Clin Virol 2013; 58 Suppl 1:e127.</a></li><li><a class="nounderline abstract_t">Prazuck T, Yameogo JM, Heylinck B, et al. Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection: a cohort study in Banfora, Burkina Faso. Pediatr Infect Dis J 1995; 14:940.</a></li><li><a class="nounderline abstract_t">Gottlieb GS, Hawes SE, Agne HD, et al. Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission. AIDS 2006; 20:895.</a></li><li><a class="nounderline abstract_t">Burgard M, Jasseron C, Matheron S, et al. Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1. Clin Infect Dis 2010; 51:833.</a></li><li><a class="nounderline abstract_t">Hawes SE, Sow PS, Stern JE, et al. Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding. AIDS 2008; 22:2517.</a></li><li><a class="nounderline abstract_t">Simon F, Matheron S, Tamalet C, et al. Cellular and plasma viral load in patients infected with HIV-2. AIDS 1993; 7:1411.</a></li><li><a class="nounderline abstract_t">Christiansen CB, Jessen TE, Nielsen C, Staun-Olsen P. False negative anti-HIV-1/HIV-2 ELISAs in acute HIV-2 infection. Vox Sang 1996; 70:144.</a></li><li><a class="nounderline abstract_t">Besnier JM, Barin F, Baillou A, et al. Symptomatic HIV-2 primary infection. Lancet 1990; 335:798.</a></li><li><a class="nounderline abstract_t">Kanki PJ, Travers KU, MBoup S, et al. Slower heterosexual spread of HIV-2 than HIV-1. Lancet 1994; 343:943.</a></li><li><a class="nounderline abstract_t">Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. The HIV Infection in Newborns French Collaborative Study Group. Pediatr Infect Dis J 1994; 13:502.</a></li><li><a class="nounderline abstract_t">Adjorlolo-Johnson G, De Cock KM, Ekpini E, et al. Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast. JAMA 1994; 272:462.</a></li><li><a class="nounderline abstract_t">Marlink R, Kanki P, Thior I, et al. Reduced rate of disease development after HIV-2 infection as compared to HIV-1. Science 1994; 265:1587.</a></li><li><a class="nounderline abstract_t">Gottlieb GS, Sow PS, Hawes SE, et al. Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa. J Infect Dis 2002; 185:905.</a></li><li><a class="nounderline abstract_t">Gilbert PB, McKeague IW, Eisen G, et al. Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal. Stat Med 2003; 22:573.</a></li><li><a class="nounderline abstract_t">MacNeil A, Sarr AD, Sankalé JL, et al. Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection. J Virol 2007; 81:5325.</a></li><li><a class="nounderline abstract_t">Popper SJ, Sarr AD, Travers KU, et al. Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2. J Infect Dis 1999; 180:1116.</a></li><li><a class="nounderline abstract_t">Poulsen AG, Aaby P, Larsen O, et al. 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa. Lancet 1997; 349:911.</a></li><li><a class="nounderline abstract_t">Martinez-Steele E, Awasana AA, Corrah T, et al. Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic. AIDS 2007; 21:317.</a></li><li><a class="nounderline abstract_t">1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Recomm Rep 1992; 41:1.</a></li><li><a class="nounderline abstract_t">Ndour M, Sow PS, Coll-Seck AM, et al. AIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar, Senegal. Trop Med Int Health 2000; 5:687.</a></li><li><a class="nounderline abstract_t">De Cock KM, Odehouri K, Colebunders RL, et al. A comparison of HIV-1 and HIV-2 infections in hospitalized patients in Abidjan, Côte d'Ivoire. AIDS 1990; 4:443.</a></li><li><a class="nounderline abstract_t">Matheron S, Mendoza-Sassi G, Simon F, et al. HIV-1 and HIV-2 AIDS in African patients living in Paris. AIDS 1997; 11:934.</a></li><li><a class="nounderline abstract_t">Lucas SB, Hounnou A, Peacock C, et al. The mortality and pathology of HIV infection in a west African city. AIDS 1993; 7:1569.</a></li><li><a class="nounderline abstract_t">Ariyoshi K, Schim van der Loeff M, Cook P, et al. Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8. J Hum Virol 1998; 1:193.</a></li><li><a class="nounderline abstract_t">Hawes SE, Critchlow CW, Faye Niang MA, et al. Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections. J Infect Dis 2003; 188:555.</a></li><li><a class="nounderline abstract_t">Gottlieb GS, Rosenberg JM, Gonzalez RG, Gandhi RT. Case 27-2020: A 53-Year-Old Woman with Headache and Gait Imbalance. N Engl J Med 2020; 383:859.</a></li><li class="breakAll">Anti-HIV-1/2 and HIV-1 Antigen Combo Assays (detect HIV-1 antigen and antibodies to HIV Types 1 and 2). Complete List of Donor Screening Assays for Infectious Agents and HIV Diagnostic Assays. US Food and Drug Administration. Available at: https://www.fda.gov/vaccines-blood-biologics/complete-list-donor-screening-assays-infectious-agents-and-hiv-diagnostic-assays#Anti-HIV-1/2%20and%20HIV-1%20Antigen%20Combo%20Assays%20(detect%20HIV-1%20antigen%20and%20antibodies%20to%20HIV%20Types%201%20and%202) (Accessed on December 01, 2022).</li><li class="breakAll">Pathology Associates Medical Laboratories. Logical Observation Identifiers Names and Codes (LOINC). Available at: https://loinc.org/adopters/pathology-associates-medical-laboratories/ (Accessed on December 01, 2022).</li><li class="breakAll">http://www.questdiagnostics.com/testcenter/TestDetail.action?ntc=34977 (Accessed on December 01, 2022).</li><li><a class="nounderline abstract_t">Chang M, Wong AJ, Raugi DN, et al. Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm. J Clin Virol 2017; 86:56.</a></li><li class="breakAll">Accessible Molecular HIV Testing in 52 Minutes Reduces Delays in Early Infant Diagnosis. Abbott. Available at: https://www.globalpointofcare.abbott/en/product-details/alere-q-hiv-12-detect.html. (Accessed on January 26, 2023).</li><li class="breakAll">The POC Alere q HIV-1/2 Detect Test for Detection and Quantification of HIV-2. Conference on Retroviruses and Opportunistic Infections. Available at: http://www.croiconference.org/sessions/poc-alere-q-hiv-12-detect-test-detection-and-quantification-hiv-2 (Accessed on February 22, 2016).</li><li><a class="nounderline abstract_t">Chang M, Steinmetzer K, Raugi DN, et al. Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1/2 Detect nucleic acid test. J Clin Virol 2017; 97:22.</a></li><li><a class="nounderline abstract_t">O'Brien TR, George JR, Epstein JS, et al. Testing for antibodies to human immunodeficiency virus type 2 in the United States. MMWR Recomm Rep 1992; 41:1.</a></li><li><a class="nounderline abstract_t">Centers for Disease Control and Prevention (CDC). HIV-2 Infection Surveillance--United States, 1987-2009. MMWR Morb Mortal Wkly Rep 2011; 60:985.</a></li><li class="breakAll">Laboratory testing for the diagnosis of HIV infection: updated recommendations. Centers for Disease Control and Prevention. Available at: https://stacks.cdc.gov/view/cdc/23447. (Accessed on January 26, 2023).</li><li><a class="nounderline abstract_t">Gottlieb GS, Smith RA, Sow PS. Long-term nonprogressive disease among individuals with untreated HIV infection. JAMA 2010; 304:1784; author reply 1785.</a></li><li class="breakAll">Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/en/guidelines/hiv-clinical-guidelines-adult-and-adolescent-arv/whats-new-guidelines. (Accessed on January 26, 2023).</li></ol></div><div id="topicVersionRevision">Topic 16727 Version 21.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21367732" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Update on human immunodeficiency virus (HIV)-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8638160" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Prognosis in HIV-1 infection predicted by the quantity of virus in plasma.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9182471" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Plasma viral load and CD4+ lymphocytes as prognostic markers of HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9424041" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Prognostic indicators for AIDS and infectious disease death in HIV-infected injection drug users: plasma viral load and CD4+ cell count.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18434556" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Quality control assessment of human immunodeficiency virus type 2 (HIV-2) viral load quantification assays: results from an international collaboration on HIV-2 infection in 2006.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21813718" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : An international collaboration to standardize HIV-2 viral load assays: results from the 2009 ACHI(E)V(2E) quality control study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22832059" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Validation for clinical use of a novel HIV-2 plasma RNA viral load assay using the Abbott m2000 platform.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24342472" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : Validation and clinical use of a sensitive HIV-2 viral load assay that uses a whole virus internal control.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8584359" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Mother-to-child transmission of human immunodeficiency virus type 1 and type 2 and dual infection: a cohort study in Banfora, Burkina Faso.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16549974" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Lower levels of HIV RNA in semen in HIV-2 compared with HIV-1 infection: implications for differences in transmission.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20804413" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Mother-to-child transmission of HIV-2 infection from 1986 to 2007 in the ANRS French Perinatal Cohort EPF-CO1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19005275" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Lower levels of HIV-2 than HIV-1 in the female genital tract: correlates and longitudinal assessment of viral shedding.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7904166" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Cellular and plasma viral load in patients infected with HIV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8740005" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : False negative anti-HIV-1/HIV-2 ELISAs in acute HIV-2 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1969547" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Symptomatic HIV-2 primary infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7909009" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Slower heterosexual spread of HIV-2 than HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8078737" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Comparison of vertical human immunodeficiency virus type 2 and human immunodeficiency virus type 1 transmission in the French prospective cohort. The HIV Infection in Newborns French Collaborative Study Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8040982" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Prospective comparison of mother-to-child transmission of HIV-1 and HIV-2 in Abidjan, Ivory Coast.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7915856" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Reduced rate of disease development after HIV-2 infection as compared to HIV-1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11920314" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Equal plasma viral loads predict a similar rate of CD4+ T cell decline in human immunodeficiency virus (HIV) type 1- and HIV-2-infected individuals from Senegal, West Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12590415" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Comparison of HIV-1 and HIV-2 infectivity from a prospective cohort study in Senegal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17329334" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Direct evidence of lower viral replication rates in vivo in human immunodeficiency virus type 2 (HIV-2) infection than in HIV-1 infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10479138" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Lower human immunodeficiency virus (HIV) type 2 viral load reflects the difference in pathogenicity of HIV-1 and HIV-2.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9093252" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : 9-year HIV-2-associated mortality in an urban community in Bissau, west Africa.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17255738" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Is HIV-2- induced AIDS different from HIV-1-associated AIDS? Data from a West African clinic.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1361652" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : 1993 revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11044262" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : AIDS caused by HIV1 and HIV2 infection: are there clinical differences? Results of AIDS surveillance 1986-97 at Fann Hospital in Dakar, Senegal.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2164821" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : A comparison of HIV-1 and HIV-2 infections in hospitalized patients in Abidjan, Côte d'Ivoire.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9189224" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : HIV-1 and HIV-2 AIDS in African patients living in Paris.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/7904450" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : The mortality and pathology of HIV infection in a west African city.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10195242" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Kaposi's sarcoma in the Gambia, West Africa is less frequent in human immunodeficiency virus type 2 than in human immunodeficiency virus type 1 infection despite a high prevalence of human herpesvirus 8.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12898443" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Increased risk of high-grade cervical squamous intraepithelial lesions and invasive cervical cancer among African women with human immunodeficiency virus type 1 and 2 infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32846066" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Case 27-2020: A 53-Year-Old Woman with Headache and Gait Imbalance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32846066" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Case 27-2020: A 53-Year-Old Woman with Headache and Gait Imbalance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32846066" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Case 27-2020: A 53-Year-Old Woman with Headache and Gait Imbalance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32846066" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Case 27-2020: A 53-Year-Old Woman with Headache and Gait Imbalance.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27951466" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27951466" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27951466" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Clinical validation of a novel diagnostic HIV-2 total nucleic acid qualitative assay using the Abbott m2000 platform: Implications for complementary HIV-2 nucleic acid testing for the CDC 4th generation HIV diagnostic testing algorithm.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29096389" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Detection and differentiation of HIV-2 using the point-of-care Alere q HIV-1/2 Detect nucleic acid test.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1324395" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Testing for antibodies to human immunodeficiency virus type 2 in the United States.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21796096" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : HIV-2 Infection Surveillance--United States, 1987-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21796096" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : HIV-2 Infection Surveillance--United States, 1987-2009.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20978256" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Long-term nonprogressive disease among individuals with untreated HIV infection.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
